PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer

MLA

Li X, et al. “PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer.” Journal of Inflammation Research, vol. ume 15, Sept. 2022, pp. 5439–55. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.046f204fb0bb4f06a6021d08814c1950&authtype=sso&custid=ns315887.

APA

Li X, Fan Y, Tang M, Li H, Zhang Y, Mi J, Wang Y, Zhao M, Wang Z, & Su F. (2022). PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. Journal of Inflammation Research, ume 15, 5439–5455.

Chicago

Li X, Fan Y, Tang M, Li H, Zhang Y, Mi J, Wang Y, Zhao M, Wang Z, and Su F. 2022. “PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer.” Journal of Inflammation Research ume 15 (September): 5439–55. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.046f204fb0bb4f06a6021d08814c1950&authtype=sso&custid=ns315887.